Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 179 | 60 | 116 |
| Samples | 171 | 58 | 110 |
| Peptides | 128 | 37 | 95 |
Function
CLEC4G · C-type lectin domain family 4 member G
This gene encodes a glycan-binding receptor and member of the C-type lectin family which plays a role in the immune response. C-type lectin receptors are pattern recognition receptors located on immune cells that play a role in the recognition and uptake of both self and non-self glycoproteins as well as mediating cell adhesion, glycoprotein clearance, and cell signaling functions. This gene's protein binds complex-type N-glycans of the viral envelope proteins of Ebola virus, West Nile filovirus, and SARS coronavirus, but not HIV or hepatitis C virus. In mouse, this protein has been shown to recognize activated T-cells and to negatively regulate T-cell receptor-mediated signalling. It also acts as a novel, liver-specific regulator of NK cell-mediated immunity in mouse. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2020].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000328853 | Q6UXB4 | 178 | 127 |
| ENST00000676742 | A0A7I2V4U5* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 127 amino-acid changes on canonical ENST00000328853 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CLEC4G · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CLEC4G – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 7/612 1% |
| Rhabdomyosarcoma | 3/33 9% | 0/171 0% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Neuroendocrine Tumour | 3/154 2% | 3/577 1% |
| Colorectal Carcinoma | 12/143 8% | 13/3239 0% |
| Thyroid Gland Carcinoma | 3/45 7% | 9/1592 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 8/1390 1% |
| Melanoma | 1/210 0% | 14/1899 1% |
| Other Solid Cancers | 1/94 1% | 10/1515 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 5/810 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Gastric Carcinoma | 2/74 3% | 8/1809 0% |
| Bladder Carcinoma | 1/58 2% | 4/956 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 5/2550 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Head and Neck Carcinoma | 0/85 0% | 4/1574 0% |
| Hepatocellular Carcinoma | 0/46 0% | 5/2210 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 2/2534 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
| Glioma | 1/52 2% | 2/2127 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Pancreatic Carcinoma | 1/89 1% | 1/1611 0% |
| Breast Carcinoma | 2/144 1% | 2/3264 0% |
Mutation Distribution
Where CLEC4G is mutated · all tissues, split by cell line vs tissue
How many mutations in CLEC4G were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 179 mutations in CLEC4G
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|